32765225|t|Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide Against Cognitive Decline in Neurodegenerative Diseases.
32765225|a|Cognitive impairment is one of the major symptoms in most neurodegenerative disorders such as Alzheimer's (AD), Parkinson (PD), and Huntington diseases (HD), affecting millions of people worldwide. Unfortunately, there is no treatment to cure or prevent the progression of those diseases. Cognitive impairment has been related to neuronal cell death and/or synaptic plasticity alteration in important brain regions, such as the cerebral cortex, substantia nigra, striatum, and hippocampus. Therefore, compounds that can act to protect the neuronal loss and/or to reestablish the synaptic activity are needed to prevent cognitive decline in neurodegenerative diseases. Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) are two highly related multifunctional neuropeptides widely distributed in the central nervous system (CNS). PACAP and VIP exert their action through two common receptors, VPAC1 and VPAC2, while PACAP has an additional specific receptor, PAC1. In this review article, we first presented evidence showing the therapeutic potential of PACAP and VIP to fight the cognitive decline observed in models of AD, PD, and HD. We also reviewed the main transduction pathways activated by PACAP and VIP receptors to reduce cognitive dysfunction. Furthermore, we identified the therapeutic targets of PACAP and VIP, and finally, we evaluated different novel synthetic PACAP and VIP analogs as promising pharmacological tools.
32765225	22	72	Pituitary Adenylate Cyclase-Activating Polypeptide	Gene	116
32765225	77	106	Vasoactive Intestinal Peptide	Gene	7432
32765225	115	132	Cognitive Decline	Disease	MESH:D003072
32765225	136	162	Neurodegenerative Diseases	Disease	MESH:D019636
32765225	164	184	Cognitive impairment	Disease	MESH:D003072
32765225	222	249	neurodegenerative disorders	Disease	MESH:D019636
32765225	258	269	Alzheimer's	Disease	MESH:D000544
32765225	271	273	AD	Disease	MESH:D000544
32765225	276	285	Parkinson	Disease	MESH:D010302
32765225	287	289	PD	Disease	MESH:D010300
32765225	296	315	Huntington diseases	Disease	MESH:D006816
32765225	317	319	HD	Disease	MESH:D006816
32765225	453	473	Cognitive impairment	Disease	MESH:D003072
32765225	703	716	neuronal loss	Disease	MESH:D009410
32765225	783	800	cognitive decline	Disease	MESH:D003072
32765225	804	830	neurodegenerative diseases	Disease	MESH:D019636
32765225	832	882	Pituitary adenylate cyclase-activating polypeptide	Gene	116
32765225	884	889	PACAP	Gene	116
32765225	895	924	vasoactive intestinal peptide	Gene	7432
32765225	926	929	VIP	Gene	7432
32765225	1040	1045	PACAP	Gene	116
32765225	1050	1053	VIP	Gene	7432
32765225	1103	1108	VPAC1	Gene	7433
32765225	1113	1118	VPAC2	Gene	7434
32765225	1126	1131	PACAP	Gene	116
32765225	1169	1173	PAC1	Gene	117
32765225	1264	1269	PACAP	Gene	116
32765225	1274	1277	VIP	Gene	7432
32765225	1291	1308	cognitive decline	Disease	MESH:D003072
32765225	1331	1333	AD	Disease	MESH:D000544
32765225	1335	1337	PD	Disease	MESH:D010300
32765225	1343	1345	HD	Disease	MESH:D006816
32765225	1408	1413	PACAP	Gene	116
32765225	1442	1463	cognitive dysfunction	Disease	MESH:D003072
32765225	1519	1524	PACAP	Gene	116
32765225	1529	1532	VIP	Gene	7432
32765225	1586	1591	PACAP	Gene	116
32765225	1596	1599	VIP	Gene	7432
32765225	Bind	7432	7433
32765225	Negative_Correlation	MESH:D003072	116
32765225	Negative_Correlation	MESH:D000544	7432
32765225	Association	116	117
32765225	Association	MESH:D019636	7432
32765225	Bind	7432	7434
32765225	Bind	116	7433
32765225	Negative_Correlation	MESH:D003072	7432
32765225	Bind	116	7434
32765225	Negative_Correlation	MESH:D006816	116
32765225	Negative_Correlation	MESH:D010300	116
32765225	Negative_Correlation	MESH:D000544	116
32765225	Negative_Correlation	MESH:D006816	7432
32765225	Negative_Correlation	MESH:D010300	7432

